

December 11, 2018



REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018

HOUSTON, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced a reminder it will host a conference call to discuss the recent discovery of a use of one of its molecules for cancer treatment and provide a business update. The call will be at 4:30 p.m. ET on Wednesday, December 12, 2018.

Participants can dial (800) 860-2442 or (412) 858-4600 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the Company's website at www.moleculin.com. A webcast replay will be available in the Investors section of the Company's website at www.moleculin.com for 90 days. A teleconference replay will be available at (877) 344-7529 or (412) 317-0088, confirmation code 10126965, through December 19, 2018.

All interested parties may submit questions via email to info@moleculin.com; management will attempt to answer these questions, time permitting during the call.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on discoveries made at M.D. Anderson Cancer Center. The Company's clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. Moleculin Biotech is also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

For more information about the Company, please visit <http://www.moleculin.com>.

Contacts

Joe Dorame, Robert Blum or Joe Diaz
Lytham Partners, LLC

602-889-9700

mbrx@lythampartners.com



Source: Moleculin Biotech, Inc.